Somatic Evolution of Acquired Drug Resistance in Cancer

Chapter
Part of the Molecular and Translational Medicine book series (MOLEMED)

Abstract

Acquired drug resistance is a central problem in cancer medicine. The diverse molecular mechanisms of acquired drug resistance all arise through the same process of somatic (within-body) cellular evolution. Even targeted drugs are subject to this failure. Genetic instability causes high genetic diversity among the cells of most cancers, but because somatic evolution results from selection as well as mutation, some classes of therapies are less prone than others to failure through acquired resistance. Cytotoxins, whether targeted or not, are especially prone to acquired drug resistance. Among the most promising classes of therapies expected to be robust against acquired resistance are: those that target systemic cancer symptoms instead of cancer cells, those that target cell motility rather than survival and proliferation, and those that target secreted metabolites of cancer cells rather than the cells themselves.

Keywords

Somatic evolution Clonal selection Systemic pathology Cell motility Public goods 

References

  1. 1.
    Lewontin RC. The units of selection. Annu Rev Ecol Syst. 1970;1:1–18.CrossRefGoogle Scholar
  2. 2.
    Gould SJ. Gulliver’s further travels: the necessity and difficulty of a hierarchical theory of selection. Philos Trans R Soc Lond B. 1998;353:307–14.CrossRefGoogle Scholar
  3. 3.
    Keller LK. Levels of selection in evolution. Princeton: Princeton University Press; 1999.Google Scholar
  4. 4.
    Cairns J. Mutation selection and the natural history of cancer. Nature. 1975;255:197–200.PubMedCrossRefGoogle Scholar
  5. 5.
    Leroi AM, Koufopanou V, Burt A. Cancer selection. Nat Rev Cancer. 2003;3:226–31.PubMedCrossRefGoogle Scholar
  6. 6.
    Summers K, da Silva J, Farwell M. Intragenomic conflict and cancer. Med Hypotheses. 2002;59:170–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Weinstein BS, Ciszek D. The reserve-capacity hypothesis: evolutionary origins and modern implications of the trade-off between tumor-suppression and tissue-repair. Exp Gerontol. 2002;37:615–27.PubMedCrossRefGoogle Scholar
  8. 8.
    Frank SA, Nowak MA. Problems of somatic mutation and cancer. Bioessays. 2004;26:291–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Campisi J. Aging, tumor suppression and cancer: high wire-act! Mech Ageing Dev. 2005;126:51–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Crespi B, Summers K. Evolutionary biology of cancer. Trends Ecol Evol. 2005;20:545–52.PubMedCrossRefGoogle Scholar
  11. 11.
    Pepper JW, Sprouffske K, Maley CC. Animal cell differentiation patterns suppress somatic evolution. PLoS Comput Biol. 2007;3:2532–45.CrossRefGoogle Scholar
  12. 12.
    Greaves M. Darwinian medicine: a case for cancer. Nat Rev Cancer. 2007;7:213–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability – an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11:220–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Merlo LMF, Wang L, Pepper JW, Rabinovitch PS, Maley CC. Chapter 1: Polyploidy, aneuploidy and the evolution of cancer. In: Poon RYC, editor. Polyploidization and cancer. Austin: Landes Bioscience; 2010. p. 1–13.CrossRefGoogle Scholar
  15. 15.
    Huang Q, Yu GP, McCormick SA, Mo J, Datta B, Mahimkar M, et al. Genetic differences detected by comparative genomic hybridization in head and neck squamous cell carcinomas from different tumor sites: construction of oncogenetic trees for tumor progression. Genes Chromosom Cancer. 2002;34:224–33.PubMedCrossRefGoogle Scholar
  16. 16.
    Siegmund KD, Marjoram P, Woo YJ, Tavare S, Shibata D. Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers. Proc Natl Acad Sci USA. 2009;106:4828–33.PubMedCrossRefGoogle Scholar
  17. 17.
    Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009;138:822–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Merlo LMF, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006;6:924–35.PubMedCrossRefGoogle Scholar
  19. 19.
    Pepper JW, Findlay CS, Kassen R, Spencer SL, Maley CC. Cancer research meets evolutionary biology. Evol Appl. 2009;2(1):62–70.CrossRefGoogle Scholar
  20. 20.
    Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786–92.PubMedCrossRefGoogle Scholar
  21. 21.
    Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876–80.PubMedCrossRefGoogle Scholar
  22. 22.
    Wang TL et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA. 2004;101:3089–94.PubMedCrossRefGoogle Scholar
  23. 23.
    Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol. 2005;45:872–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, et al. Dynamics of chronic myeloid leukaemia. Nature. 2005;435:1267–70.PubMedCrossRefGoogle Scholar
  25. 25.
    Williams PD. Darwinian interventions: taming pathogens through evolutionary ecology. Trends Parasitol. 2010;26:83–92.PubMedCrossRefGoogle Scholar
  26. 26.
    Wargo AR, Huijben S, de Roode JC, Shepherd J, Read AF. Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. Proc Natl Acad Sci USA. 2007;104:19914–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Gatenby RA. A change of strategy in the war on cancer. Nature. 2009;459:508–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Chabner BA, Roberts TG. Chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5:65–72.PubMedCrossRefGoogle Scholar
  29. 29.
    Garber K. Melanoma drug vindicates targeted approach. Science. 2009;326:1619.PubMedCrossRefGoogle Scholar
  30. 30.
    Deisboeck TS, Couzin ID. Collective behavior in cancer cell populations. Bioessays. 2009;31:190–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Laviano A, Meguid MM, Inui A, Muscaritoli M, Rossi-Fanelli F. Therapy Insight: cancer anorexia-cachexia syndrome – when all you can eat is yourself. Nat Clin Pract Gastroenterol Hepatol. 2005;2:B158–65.CrossRefGoogle Scholar
  32. 32.
    Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Fanelli FR. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer. 2006;42:31–41.PubMedCrossRefGoogle Scholar
  33. 33.
    Evans C, Dalgleish AG, Kumar D. Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther. 2006;24:1163–77.PubMedCrossRefGoogle Scholar
  34. 34.
    Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 2006;16:3–15.PubMedCrossRefGoogle Scholar
  35. 35.
    Herber DL, Nagaraj S, Djeu JY, Gabrilovich DI. Mechanism and therapeutic reversal of immune suppression in cancer. Cancer Res. 2007;67:5067–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Torres MP, Ponnusamy MP, Lakshmanan I, Batra SK. Immunopathogenesis of ovarian cancer. Minerva Medica. 2009;100:385–400.PubMedGoogle Scholar
  37. 37.
    Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3:362–74.PubMedCrossRefGoogle Scholar
  38. 38.
    Wang WG, Goswami S, Sahai E, Wyckoff JB, Segall JE, Condeelis JS. Tumor cells caught in the act of invading: their strategy for enhanced cell motility. Trends Cell Biol. 2005;15:138–45.PubMedCrossRefGoogle Scholar
  39. 39.
    Mouneimne G, Brugge JS. Tensins: a new switch in cell migration. Dev Cell. 2007;13:317–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br J Cancer. 2007;96:1–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Pepper JW. Defeating pathogen drug resistance: guidance from evolutionary theory. Evolution. 2008;62:3185–91.PubMedCrossRefGoogle Scholar
  42. 42.
    Driscoll WW, Pepper JW. Theory for the evolution of diffusible external goods. Evolution. 2010;64:2682–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Kerbel RS. A cancer therapy resistant to resistance. Nature. 1997;390:335–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Boehm T, Folkman J, Browder T, O’Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res. 2003;63:3847–54.PubMedGoogle Scholar
  46. 46.
    Brunner N, Dano K. Invasion and metastasis factors in breast cancer. Breast Cancer Res Treat. 1993;24:173–4.CrossRefGoogle Scholar
  47. 47.
    Farias EF, Ghiso JAA, Ladeda V, Joffe EBD. Verapamil inhibits tumor protease production, local invasion and metastasis development in murine carcinoma cells. Int J Cancer. 1998;78:727–34.PubMedCrossRefGoogle Scholar
  48. 48.
    Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007;9:556–62.PubMedCrossRefGoogle Scholar
  49. 49.
    Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 2007;67:9417–24.PubMedCrossRefGoogle Scholar
  50. 50.
    Aktipis CA, Maley CC, Pepper JW. Dispersal evolution in neoplasms: the role of disregulated metabolism in the evolution of cell motility. Cancer Prevention Res. 2011; in press.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of Cancer PreventionNational Cancer InstituteBethesdaUSA

Personalised recommendations